Our work and case studies

Challenge: Process chemistry route to API required hydrogenation, then salt formation. The hydrogenation product was chemically unstable until the salt was formed. On a large scale, this was adequately controlled.

In radiochemical trials, the larger dilution and higher catalyst loading required for the very small-scale synthesis led to increased degradation of the unstable intermediate and unacceptable yield.

Customer:

US Biopharmaceutical Company

Outcome:

A flow hydrogenation reactor was used; as the chemically unstable product was formed it was fed directly into the salt formation vessel. This greatly reduced degradation.

Successful [14C]synthesis was carried out to support both non-clinical and clinical trials. 

 

ICMS Radiosynthesis Case Study